NASDAQ: TNDM · Medical Devices

Tandem Diabetes Care (TNDM) fair value and price range

As of 14 Nov 2026, Faircurve's model values Tandem Diabetes Care (TNDM) at $21.89 a share. The stock last closed at $18.48, which puts the model's fair value 18.5% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

Revalued . Price is the close of 16 Nov 2026. Tandem Diabetes Care, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$21.89midpoint of 2,000 simulations
Last close$18.48NASDAQ: TNDM
Gap to fair value+18.5%fair value against price
Model verdictLow evidence gradeevidence grade: Low

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $21.00 to $21.89 (+4.2%). The multiple the model anchors on moved, lifting the fair value: most of the move.

What the model makes of itThe price of $18.48 is 18.5% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What's nextNext report on 18 Feb 2027. Options prices imply a move of about 23% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give TNDM?

The calibrated range for TNDM over 63 trading days is $14.20 to $24.38. It sits around the last close, and its width comes from the volatility that TNDM's own options imply (80% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $16.18 to $28.12. In 60% of the simulations the fair value came out above the price the model ran on.

$10.51$40.17
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $21.89. Dashed line: the last close, $18.48.

Faircurve Insights · 14 Nov 2026

Tandem Diabetes Care, Inc. (TNDM) is a medical technology firm. It specialises in creating, developing and marketing solutions for individuals globally who manage insulin-dependent diabetes.

Faircurve's model put the fair value on 14 Nov 2026 at $21.89 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $21.00, so the fair value moved +4.2%. In the model's own words, the multiple it anchors on moved, lifting the fair value: most of the move. The calibrated range over 63 trading days is $15.11 to $27.05, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence as low, so no verdict is shown. The grade covers input completeness, comparable companies and range width. It does not say whether the fair value is right.

The model's overall quality score is 50 out of 100, a composite of six factors scored against comparable companies. Earnings quality scores 77. Profitability scores 22, with ROIC at -3.2% against a peer median of -27.2%. Stability scores 35, with five-year EBITDA margin downside volatility at 7.2 pts against a peer median of 33.4 pts. The comparable companies are Enovis Corporation (ENOV), Integra LifeSciences Holdings Corporation (IART), Artivion, Inc. (AORT), UFP Technologies, Inc. (UFPT) and Neogen Corporation (NEOG).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does TNDM report earnings, and how has the stock reacted?

Tandem Diabetes Care's next earnings report is scheduled for 18 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 18.6% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. TNDM's 30 day implied volatility works out to about 23.1% over one month.

On 13 Nov 2026 TNDM moved 14.6% in one session, against the 5.4% a day that options had priced: 2.7 times the implied size.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across TNDM's last 8 reports, ignoring direction, was 14.2%.

0%10%20%30%19.1%0.6%6 Nov '2417.9%34.8%26 Feb '2519.7%24.0%6 Aug '2518.9%10.8%6 Nov '2521.8%29.7%19 Feb '2618.0%14.1%7 May '2620.1%14.2%6 Aug '2621.6%11.2%5 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in TNDM

10%15%20%25%30%35%5 Nov '26 report6 Aug '26 report7 May '26 report19 Feb '26 report23% at 16 Nov '2612 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 21% on 12 Nov 2025, reached 30% on 6 Nov 2026 and reads 23% on 16 Nov 2026. The marks are report dates.

How does TNDM score on business quality?

Tandem Diabetes Care's overall quality score is 50 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.22-3.2%ROIC-27.2%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).77
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.507.9%Revenue growth, trailing37.2%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.750.0%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.70-38.80xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.357.2 ptsEBITDA margin downside volatility, 5y33.4 pts

How does TNDM compare with similar companies?

The companies in medical devices closest to Tandem Diabetes Care in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
CNMD CONMED Corporation$49.35$50.43+2.2%Low evidence grade
ENOV Enovis Corporation$27.92$32.77+17.4%Undervalued
IART Integra LifeSciences Holdings Corporation$13.98$16.00+14.4%Fairly valued
INSP Inspire Medical Systems, Inc.$59.12$61.27+3.6%Low evidence grade
AHCO AdaptHealth Corp.$7.73$7.47-3.4%Low evidence grade
AORT Artivion, Inc.$18.47$20.28+9.8%Fairly valued
UFPT UFP Technologies, Inc.$298.54$266.65-10.7%Fairly valued
NEOG Neogen Corporation$10.88$10.11-7.1%Fairly valued

What the comparable companies' multiples alone would give for TNDM, the peer-implied price, is $31.42 a share on this run. The fair value weighs that against the company's own multiple.

All medical device stocks ranked by gap to fair value

Tandem Diabetes Care at a glance

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes.

Market value
$1.4B
Sector
Healthcare
Industry
Medical Devices
Revenue expected, next twelve months
$1.1B
Consensus revenue growth, next fiscal year
+6.1%
Analysts with estimates
14
Beta to the US market
0.90
First valued by Faircurve
11 Jul 2026

How the fair value is worked out: the model prices Tandem Diabetes Care on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for TNDM was $21.00. As of 14 Nov 2026 it is $21.89, a change of +4.2%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Tandem Diabetes Care's valuation

Is Tandem Diabetes Care stock undervalued or overvalued?

Faircurve's model puts TNDM's fair value at $21.89 a share against a last close of $18.48, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.

What is TNDM's fair value?

$21.89 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $16.18 to $28.12.

What price range does the model give TNDM?

$14.20 to $24.38 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Tandem Diabetes Care report earnings next?

The next report is scheduled for 18 Feb 2027. Companies can move their dates.

How much has TNDM moved on past earnings reports?

Across its last 8 reports the median two session move was 14.2%, ignoring direction. The largest was -34.8% around the report of 26 Feb 2025.

How confident is the model in this valuation?

The model's evidence grade for TNDM is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on TNDM

The model holds no idea open on TNDM today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on TNDM with their outcomes. A free account is enough.

Keep reading